LAG3 / CD223 Immune Checkpoint Inhibitors

LAG3 / CD223 immune checkpoint inhibitors are a kind of drugs, which are designed to target LAG3 / CD223 immune checkpoint molecules. These LAG3 / CD223 are inhibitory immune checkpoint molecules, so that the LAG3 / CD223 immune checkpoint inhibitors can enhance immunity to cancers. BMS-986016 is one of the LAG3 / CD223 immune checkpoint inhibitors, and can be used to treat Lymphoma and some solid cancers.

LAG3 / CD223 Immune Checkpoint Inhibitors: Developments

Disease LAG3 / CD223 immune checkpoint inhibitors research development
Lymphoma BMS-986016 —— A phase I study of BMS-986016 (LAG3 / CD223 immune checkpoint inhibitors drug) in adult patients with hematologic cancers (NCT02061761).
Other BMS-986016 —— a phase I trial to test BMS-986016, a LAG3 / CD223 immune checkpoint inhibitors antibody, with or without nivolumab (anti-PD-1), in patients with solid tumors (NCT01968109).